Pharming Group N.V. announces that the US Food and Drug Administration (FDA) has approved Joenja® (leniolisib), to treat the rare primary immunodeficiency activated phosphoinositide 3-kinase delta syndrome (APDS) in adults and adolescents 12 years of age and older in the US. Joenja®, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, is the first and only treatment approved in the US for APDS, a rare and progressive primary immunodeficiency.
Pharming Announces US FDA Approval of Joenja® to treat APDS
Published: April 5, 2023